Evidence map›Paper›PMID 28867149›Full record

ArticleNeurobiology of aging2017

Establishing the role of rare coding variants in known Parkinson's disease risk loci.

Iris E Jansen, J Raphael Gibbs, Mike A Nalls, T Ryan Price, Steven Lubbe, Jeroen van Rooij, André G Uitterlinden, Robert Kraaij, Nigel M Williams, Alexis Brice and 8 more

Abstract read
In one paragraph

Article in Neurobiology of aging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Pathogenic Single Nucleotide Polymorphisms on Autophagy-Related Genes.International journal of molecular sciences · 2020
    Review
  6. Utility and implications of exome sequencing in early-onset Parkinson's disease.Movement disorders : official journal of the Movement Disorder Society · 2019
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Iris E JansenDepartment of Clinical Genetics, VU University Medical Center, Amsterdam, the Netherlands; Genome Biology of Neurodegenerative Diseases, German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.
J Raphael GibbsLaboratory of Neurogenetics, National Institute on Aging, Bethesda, MD, USA.
Mike A NallsLaboratory of Neurogenetics, National Institute on Aging, Bethesda, MD, USA; Data Tecnica International, Glen Echo, MD, USA.
T Ryan PriceUniversity California Irvine, Irvine, CA, USA.
Steven LubbeKen and Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Jeroen van RooijDepartment of Internal Medicine, Erasmus MC, Rotterdam, the Netherlands.
André G UitterlindenDepartment of Internal Medicine, Erasmus MC, Rotterdam, the Netherlands; Netherlands Consortium for Healthy Ageing (NCHA), Rotterdam, the Netherlands; Department of Epidemiology, Erasmus MC, Rotterdam, the Netherlands.
Robert KraaijDepartment of Internal Medicine, Erasmus MC, Rotterdam, the Netherlands; Netherlands Consortium for Healthy Ageing (NCHA), Rotterdam, the Netherlands; Department of Epidemiology, Erasmus MC, Rotterdam, the Netherlands.
Nigel M WilliamsMRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, Wales, UK.
Alexis BriceInserm U1127, CNRS UMR7225, Sorbonne Universités, UPMC Univ Paris 06, UMR_S1127, Institut du Cerveau et de la Moelle épinière, Paris, France; Assistance Publique Hôpitaux de Paris, Hôpital de la Salpêtrière, Département de Génétique et Cytogénétique, Paris, France.
John HardyReta Lila Weston Institute, University College London, London, UK.
Nicholas W WoodDepartment of Clinical Neuroscience, UCL Institute of Neurology, London, UK.
Huw R MorrisDepartment of Clinical Neuroscience, UCL Institute of Neurology, London, UK.
Thomas GasserCentre for Genetic Epidemiology, Institute for Clinical Epidemiology and Applied Biometry, University of Tübingen, Tübingen, Germany.
Andrew B SingletonLaboratory of Neurogenetics, National Institute on Aging, Bethesda, MD, USA.
Peter HeutinkGenome Biology of Neurodegenerative Diseases, German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany; Centre for Genetic Epidemiology, Institute for Clinical Epidemiology and Applied Biometry, University of Tübingen, Tübingen, Germany.
Manu SharmaCentre for Genetic Epidemiology, Institute for Clinical Epidemiology and Applied Biometry, University of Tübingen, Tübingen, Germany. Electronic address: manu.sharma@uni-tuebingen.de.
International Parkinson's Disease Genomics Consortium

Funding

Genome wide SNP analysis in Parkinson's diseaseZ01AG000949 · NIA · NATIONAL INSTITUTE ON AGING · PI SINGLETON, ANDREW B · 2006 to 2008
$2.6M
Assessment of Candidate Loci in Parkinson's diseaseZ01AG000957 · NIA · NATIONAL INSTITUTE ON AGING · PI SINGLETON, ANDREW B · 2003 to 2008
$1.2M
Intramural NIH HHS Z01 AG000949Intramural NIH HHS Z01 AG000957Medical Research Council MC_PC_09003Medical Research Council MR/L010305/1Medical Research Council MR/L501554/1NIA NIH HHS Z01 AG000949Parkinson's UK G-1107Parkinson's UK J-0804Parkinson's UK K-1501
6 · The paper itself

Abstract

Many common genetic factors have been identified to contribute to Parkinson's disease (PD) susceptibility, improving our understanding of the related underlying biological mechanisms. The involvement of rarer variants in these loci has been poorly studied. Using International Parkinson's Disease Genomics Consortium data sets, we performed a comprehensive study to determine the impact of rare variants in 23 previously published genome-wide association studies (GWAS) loci in PD. We applied Prix fixe to select the putative causal genes underneath the GWAS peaks, which was based on underlying functional similarities. The Sequence Kernel Association Test was used to analyze the joint effect of rare, common, or both types of variants on PD susceptibility. All genes were tested simultaneously as a gene set and each gene individually. We observed a moderate association of common variants, confirming the involvement of the known PD risk loci within our genetic data sets. Focusing on rare variants, we identified additional association signals for LRRK2, STBD1, and SPATA19. Our study suggests an involvement of rare variants within several putatively causal genes underneath previously identified PD GWAS peaks.

Indexed as

Genome-Wide Association StudyDatasets as TopicGenetic LociGenetic Predisposition to DiseaseGenetic VariationHumansLeucine-Rich Repeat Serine-Threonine Protein Kinase-2Membrane ProteinsMitochondrial ProteinsMuscle ProteinsParkinson DiseaseRiskSeminal Plasma ProteinsLeucine-Rich Repeat Serine-Threonine Protein Kinase-2LRRK2 protein, humanMembrane ProteinsMitochondrial ProteinsMuscle ProteinsSeminal Plasma ProteinsSPATA19 protein, humanSTBD1 protein, humanCommon risk lociParkinson's diseaseRare variantsVariant aggregation testWhole exome sequencing

Identifiers

PMID28867149
PMCPMC8722270

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.